UK Delegation Highlights Life Sciences Priorities at J.P. Morgan Healthcare Conference

UK representation at the J.P. Morgan Healthcare Conference has underlined ongoing efforts to position London and the wider UK as a leading global hub for healthcare and life sciences. Writing from the first day of the conference, Howard Dawber OBE highlighted engagement with investors, entrepreneurs and industry leaders at the event, which is widely regarded as a key meeting point for the global healthcare sector.

The J.P. Morgan Healthcare Conference, held annually in San Francisco, brings together senior figures from biotechnology, pharmaceuticals, medtech and digital health, alongside institutional investors and policymakers. It is often seen as a barometer for investment trends and strategic priorities across the sector for the year ahead.

In his update, Dawber emphasised the importance of being present on the international stage to promote London’s life sciences ecosystem, noting discussions focused on innovation, investment and collaboration. Such engagement reflects broader efforts by city and national leaders to attract global capital, support research-led growth and strengthen international partnerships in high-value sectors.

Life sciences continues to feature prominently in UK economic strategy, driven by its contribution to innovation, skilled employment and long-term productivity. International conferences such as J.P. Morgan’s provide an opportunity to reinforce the UK’s strengths in research, regulation and talent, while also engaging directly with decision-makers shaping global investment flows.

The relevance of these discussions extends beyond large corporates to smaller firms operating across the healthcare and life sciences landscape. SMEs play a critical role in early-stage innovation, particularly in areas such as diagnostics, digital health and medical technology. Visibility at global forums can influence investor sentiment toward the wider ecosystem in which these smaller businesses operate.

For policymakers, engagement at events like the J.P. Morgan Healthcare Conference is increasingly viewed as part of a longer-term approach to supporting sector growth. While immediate outcomes are often difficult to quantify, sustained international presence is seen as important in maintaining competitiveness and signalling commitment to priority industries.

As the conference continues, attention will turn to how conversations held during the event translate into future investment, partnerships and policy initiatives. For the UK life sciences sector — from multinational firms to emerging SMEs — global engagement remains a key element in navigating an increasingly competitive and interconnected market.